Principal Financial Group Inc. grew its stake in shares of Xencor, Inc. (NASDAQ:XNCR) by 9.6% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 429,447 shares of the biopharmaceutical company’s stock after purchasing an additional 37,612 shares during the quarter. Principal Financial Group Inc. owned approximately 0.75% of Xencor worth $16,658,000 as of its most recent filing with the Securities and Exchange Commission.
Other hedge funds also recently added to or reduced their stakes in the company. Nisa Investment Advisors LLC raised its holdings in Xencor by 173.2% during the second quarter. Nisa Investment Advisors LLC now owns 1,120 shares of the biopharmaceutical company’s stock worth $36,000 after purchasing an additional 710 shares in the last quarter. Pacer Advisors Inc. acquired a new stake in Xencor during the third quarter worth approximately $83,000. Advisor Group Holdings Inc. acquired a new stake in Xencor during the first quarter worth approximately $139,000. Ameritas Investment Partners Inc. increased its holdings in shares of Xencor by 18.3% in the 2nd quarter. Ameritas Investment Partners Inc. now owns 4,898 shares of the biopharmaceutical company’s stock valued at $159,000 after acquiring an additional 756 shares during the period. Finally, Aigen Investment Management LP acquired a new position in shares of Xencor in the 3rd quarter valued at $175,000.
A number of brokerages have recently commented on XNCR. Zacks Investment Research cut shares of Xencor from a “hold” rating to a “sell” rating in a report on Saturday, August 8th. TheStreet raised shares of Xencor from a “d+” rating to a “c-” rating in a report on Tuesday, October 6th. BidaskClub raised shares of Xencor from a “buy” rating to a “strong-buy” rating in a report on Tuesday, September 22nd. Cantor Fitzgerald lifted their target price on shares of Xencor from $40.00 to $56.00 and gave the company an “overweight” rating in a report on Monday, November 16th. Finally, SVB Leerink boosted their price objective on shares of Xencor from $42.00 to $46.00 and gave the company an “outperform” rating in a research note on Friday, November 6th. Three research analysts have rated the stock with a sell rating, eight have issued a buy rating and one has given a strong buy rating to the stock. The company presently has a consensus rating of “Buy” and an average price target of $42.20.
Xencor (NASDAQ:XNCR) last issued its earnings results on Thursday, November 5th. The biopharmaceutical company reported ($0.22) EPS for the quarter, hitting the consensus estimate of ($0.22). Xencor had a negative net margin of 113.40% and a negative return on equity of 13.56%. As a group, equities research analysts forecast that Xencor, Inc. will post -1.7 earnings per share for the current year.
Xencor Company Profile
Xencor, Inc, a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and other protein therapeutics to treat severe and life threatening diseases with unmet medical needs. It develops its antibody product candidates to treat cancer and autoimmune diseases.
Featured Article: P/E Growth (PEG)
Want to see what other hedge funds are holding XNCR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Xencor, Inc. (NASDAQ:XNCR).
Receive News & Ratings for Xencor Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xencor and related companies with MarketBeat.com's FREE daily email newsletter.